L-cet (levocetirizine dihydrochloride) coated tablets 5 mg. №30

Description

L-cet №30 Composition
active substance: levocetirizine dihydrochloride 1 film-coated tablet contains 5 mg levocetirizine dihydrochloride
excipients: microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silicon dioxide, magnesium stearate, Opadry II 85G 51300 green coating.

L-cet №30 Indications for use
Symptomatic treatment of allergic rhinitis, including perennial allergic rhinitis
chronic idiopathic urticaria.

L-cet №30 Contraindications
Hypersensitivity to levocetirizine, cetirizine, hydroxyzine, to any other piperazine derivatives or to any other excipient of the L-CET preparation. Severe chronic renal failure (creatinine clearance <10 ml / min).

Method of administration and dosage
The drug L-CET is prescribed for adults and children over 6 years of age by mouth at a dose of 5 mg once a day, regardless of food intake. The tablet must be swallowed whole with a little water. Elderly patients with normal renal function do not need dose adjustment of L-CET. For patients with impaired renal function, the dose calculation should be carried out taking into account creatinine clearance in accordance with the table. To use this table, the dosage must be estimated by the creatinine clearance (CL cr) of the patient in ml / min. CL cr (ml / min) should be estimated by the serum creatinine content (mg / dl) using the following formula: KLkr = [140 – age (years)] x body weight (kg) (x 0.85 for women) 72 x serum creatinine (mg / dl)

Table 1. Correction of the dose of L-CET in patients with impaired renal function renal function CC, ml / min daily dose number of doses Normal renal function ≥ 80 5 mg (10 ml) 1 time per day Mild impairment 50-79 5 mg (10 ml ) 1 time per day Moderate disorder 30-49 5 mg (10 ml) 1 time per 2 days Severe degree disorder <30 5 mg (10 ml) 1 time per 3 days End stage of kidney disease. Patients on dialysis <10 are contraindicated in Children with impaired renal function, the dose of L-CET should be adjusted individually, taking into account the patient’s renal clearance and body weight. There are no specific data on the use of children with impaired renal function. Patients with impaired liver function Patients with exclusively hepatic impairment do not need to adjust the dosage regimen. Patients with hepatic and renal insufficiency need to adjust the dosage regimen in accordance with the table above. Duration of use of L-CET Patients with recurrent allergic rhinitis (duration of symptoms of the disease is less than 4 days per week or less than 4 weeks per year) should be treated according to the course of the disease and history: treatment can be discontinued if symptoms disappear and can be restored again if symptoms recur. In the case of persistent allergic rhinitis (the duration of the manifestation of symptoms of the disease is more than 4 days per week or more than 4 weeks per year) during the period of contact with allergens, the patient can be offered continuous therapy. There is clinical experience with levocetirizine for at least 6 months of treatment. In chronic diseases (chronic allergic rhinitis, chronic urticaria), the duration of treatment is up to 1 year (data are available from clinical studies with the use of racemate). CHILDREN Use L-CET in children over 6 years of age.